Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Obalon brings in $20mm via Series D and $10mm term loan

Executive Summary

Obalon Therapeutics Inc. (balloon device for weight loss) raised $20mm in Series D funding from returning backers Domain Associates, InterWest Partners, and Okapi Venture Capital, and new investors Axon Ventures, Bader Sultan & Bros., Mirae Asset Venture Investment, NeoPlux, and Striker Asia Opportunities Fund. Obalon also received a $10mm term loan from Square 1 Bank. Funds will help support US clinical trials of the Obalon balloon as the company prepares it for FDA approval.
Deal Industry
  • Medical Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies